Molecular Biomarkers & Diagnosis

Mu Wang

Publications

• Research Article
  Putative Surrogate Biomarkers to Predict Patients with Acquired Platinum Resistance in Ovarian Cancer
  Author(s): Mu Wang, Dawn P G Brown, Jinsam You and Kerry G BemisMu Wang, Dawn P G Brown, Jinsam You and Kerry G Bemis
  
  Over 15,000 women die from ovarian cancer and there are approximately 23,000 new cases diagnosed each year. Platinum-based chemotherapy is still the primary treatment for ovarian cancer. Most patients with the disease are initially responsive to chemotherapeutic treatment. However, a majority of ovarian cancer patients eventually relapse and become refractory to additional treatment. This drug-resistance is a major impediment to the successful treatment of ovarian cancer. To date the mechanisms of drug-resistance remain poorly understood. Previous studies have suggested that many proteins, such as BRCA1, BRCA2, MDR1, MRP1, MDM2, hMLH1, HSP27, and HSP70, are differentially expressed in drug-resistant ovarian tumor cells by mRNA differential display analysis. However, biomarkers that can be used to differentiate chemotherapy responders from non-responders have not yet been developed. Wi.. Read More»
  DOI: 10.4172/2155-9929.1000184

  Abstract PDF